Nexstim logo

Nexstim Plc announces signing of an Independent Selling Representative Agreements in U.S.

11 January 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that its wholly owned subsidiary Nexstim Inc. has signed Independent Selling Representative Agreements in US with SurgicalOne, Inc., NeuroTec Inc., and Medical Excellence Southwest, to represent the Nexstim Brain Mapping NBS System.  


As experienced medical and surgical distributors focused on neurosurgery, these three companies represent and sell a wide spectrum and variety of innovative technologies across 21 U.S. states, and now add the Nexstim Brain Mapping System to the portfolio.


Commenting on the events, John Liedtky, General Manager U.S. stated: "This represents positive momentum as part of the Company strategy in developing a distributor model in the U.S. We are pleased to collaborate with our new partners to continue to drive awareness and adoption of our Brain Mapping technology."



Martin Jamieson, CEO


Further information is available on the website or by telephone:


Nexstim                                                                                                                                    +447715163942

Martin Jamieson, CEO                                                                    


UB Securities Oy (Certified Adviser)                                                                         +358 (0)9 2538 0246


About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit





Back to Press Releases